← Back to Screener
Cyclerion Therapeutics, Inc. Common Stock (CYCN)
Price$2.98
Value ScoreC
Growth ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)80.68%
Price vs S&P 500 (4W)-3.86%
VGM Score51.30
Market Capitalization$12.90M
All Metrics
Book Value / Share (Quarterly)$1.60
P/TBV (Annual)0.48x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)8.36%
Cash Flow / Share (Quarterly)$-0.85
Price vs S&P 500 (YTD)126.49%
Net Profit Margin (TTM)-170.11%
EPS (TTM)$-1.37
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-1.37
Revenue Growth (5Y)-2.05%
EPS (Annual)$-1.11
ROI (Annual)-38.83%
Net Profit Margin (5Y Avg)-1544.15%
Cash / Share (Quarterly)$0.67
Revenue Growth QoQ (YoY)-43.24%
ROA (Last FY)-35.33%
Revenue Growth TTM (YoY)-4.23%
EBITD / Share (TTM)$-1.51
ROE (5Y Avg)-129.39%
Operating Margin (TTM)-176.28%
Cash Flow / Share (Annual)$-0.87
P/B Ratio1.90x
P/B Ratio (Quarterly)0.99x
Net Income / Employee (Annual)$-3,528,000
EV / Revenue (TTM)4.86x
Net Interest Coverage (TTM)-2581.50x
ROA (TTM)-55.14%
EPS Incl Extra (Annual)$-1.11
Current Ratio (Annual)5.15x
Quick Ratio (Quarterly)1.65x
3-Month Avg Trading Volume3.22M
52-Week Price Return-5.99%
Revenue / Employee (TTM)$1,993,000
Tangible BV / Share (Quarterly)$5.26
P/S Ratio (Annual)6.22x
Asset Turnover (Annual)0.21x
52-Week High$8.48
Operating Margin (5Y Avg)-1581.10%
EPS Excl Extra (Annual)$-1.11
26-Week Price Return88.61%
Quick Ratio (Annual)4.72x
13-Week Price Return114.39%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.80x
Enterprise Value$10.08M
Revenue / Share Growth (5Y)-15.50%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)-41.60%
Revenue / Employee (Annual)$2,074,000
Pretax Margin (Annual)-170.11%
Cash / Share (Annual)$0.85
3-Month Return Std Dev622.51%
Net Income / Employee (TTM)$-5,276,000
ROE (Last FY)-38.83%
EPS Basic Excl Extra (Annual)$-1.11
Receivables Turnover (TTM)6.86x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.37
Receivables Turnover (Annual)2.67x
ROI (TTM)-62.10%
P/S Ratio (TTM)6.22x
Pretax Margin (5Y Avg)-1544.15%
Revenue / Share (Annual)$0.65
Tangible BV / Share (Annual)$4.80
Price vs S&P 500 (52W)-30.36%
Year-to-Date Return134.65%
5-Day Price Return-3.25%
EPS Normalized (Annual)$-1.11
ROA (5Y Avg)-87.45%
Net Profit Margin (Annual)-170.11%
Month-to-Date Return-5.40%
Cash Flow / Share (TTM)$-7.92
EBITD / Share (Annual)$-1.15
Operating Margin (Annual)-176.28%
ROI (5Y Avg)-129.39%
EPS Basic Excl Extra (TTM)$-1.37
P/TBV (Quarterly)0.39x
P/B Ratio (Annual)0.55x
Pretax Margin (TTM)-170.11%
Book Value / Share (Annual)$2.38
Price vs S&P 500 (13W)106.13%
Beta1.80x
Revenue / Share (TTM)$0.47
ROE (TTM)-62.10%
52-Week Low$1.03
vGradeC
gGradeD
mGradeB
vgmGradeC
Show chart for
Analyst Recommendations
Feb 2023
Mar 2023
Apr 2023
May 2023
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CYCNCyclerion Therapeutics, Inc. Common Stock | C | D | B | $2.98 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases using soluble guanylate cyclase (sGC) stimulator technology. The company's pipeline includes Olinciguat, Praliciguat, and other candidates targeting rare disease indications. Cyclerion is focused on advancing next-generation sGC stimulators to address unmet medical needs in patients with limited treatment options.